Article

Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma

Research and Development Division, Tella Inc, Tokyo, Japan.
Pancreas (Impact Factor: 3.01). 07/2011; 41(2):195-205. DOI: 10.1097/MPA.0b013e31822398c6
Source: PubMed

ABSTRACT In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1.
Dendritic cell-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer [LAK] cell therapy) in combination with gemcitabine and/or S-1 has been carried out in 49 patients with inoperable pancreatic carcinoma refractory to standard treatment.
Of 49 patients, 2 patients had complete remission, 5 had partial remission, and 10 had stable disease. Prolongation of survival in this cohort was highly likely (median survival, 360 days). Survival of patients receiving DC vaccine and chemotherapy plus LAK cell therapy was longer than those receiving DC vaccine in combination with chemotherapy but no LAK cells. Increased numbers of cancer antigen-specific cytotoxic T cells and decreased regulatory T cells were observed in several patients on immunotherapy, but increased overall survival time tended to be associated only with the latter. None of the patients experienced grade 3 or worse adverse events during the treatment period.
Dendritic cell vaccine-based immunotherapy combined with chemotherapy was shown to be safe and possibly effective in patients with advanced pancreatic cancer refractory to standard treatment.

Download full-text

Full-text

Available from: Yoshikazu Yonemitsu, Nov 05, 2014
1 Follower
 · 
185 Views
  • Source
    • "Mature DCs (mDCs) were generated under Good Manufacturing Practice conditions and cryopreserved in liquid nitrogen as described previously [5], with some modification. Briefly, a PBMC-rich fraction was obtained from the HSCT donor by means of leukapheresis with the use of the COM.TEC, cell separator (Fresenius Kabi Japan K.K., Tokyo, Japan). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT. Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
    Cytotherapy 12/2014; 17(3). DOI:10.1016/j.jcyt.2014.10.003 · 3.10 Impact Factor
  • Source
    • "CEA, MAGE, HER2/neu, KLH protein. and pan-DR epitope peptide Colorectal Tamir et al., 2007 Tumor lysate Colorectal Burgdorf et al., 2008 Allogeneic tumor lysate Colorectal Lepisto et al., 2008 MUC1 peptide Pancreatic and biliary Palmer et al., 2009 Tumor lysate Hepatocellular Toh et al., 2009 Allogeneic cell lysate Colorectal Nakamura et al., 2009 Tumor lysate pulsed DCs with chemotherapy Pancreatic Lesterhuis et al., 2010 CEA mRNA transfection Colorectal Burgdorf, 2010 Allogeneic tumor cell lysate Colorectal Lesterhuis et al., 2010 Chemotherapy plus KLH and CEA peptide Colorectal Barth et al., 2010 Tumor lysate-with KLH Colorectal Onishi et al., 2011 Fusion hybrids Rectal Rong et al., 2012 MUC1-peptide-pulsed DCs Pancreatic Sakakibara et al., 2011 Autologous DCs with adjuvant Colorectal Bauer et al., 2011 Chemotherapy with tumor lysate pulsed DCs Pancreatic Kimura et al., 2012 LAK cell therapy with DC vaccine and chemotherapy "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gastrointestinal (GI) malignancies are one of the most frequently occurring tumors found worldwide. Surgery remains the primary treatment for most solid tumors and adjuvant chemotherapy and radiotherapy are limited by lack of specificity and toxicity. In view of the poor survival rate, there is a great need to introduce new and effective therapeutic modalities. Recently, dendritic cells (DCs)-based vaccines are being explored as a promising therapeutic strategy but their success is limited by the tumor-induced immune escape mechanisms. This article provides a comprehensive analysis of clinical trials conducted using this approach. It also showcases the necessity of exploring nano-engineered strategies for improving the clinical utility of DC-vaccination for GI tract malignancies to overcome immune tolerance.
    Journal of Drug Targeting 10/2013; DOI:10.3109/1061186X.2012.731069 · 2.72 Impact Factor
  • Source
    • "In this regimen, one patient had partial remission (PR) and 2 had long stable disease (SD) more than 6 months. Recently, we also reported that combination therapy of DC-based immunotherapies with gemcitabine/S-1 was effective in patients with advanced pancreatic cancer refractory to standard chemotherapy (Kimura, Imai et al., 2011). As WT1 is one of the excellent TAAs for the target of immunotherapy and is frequently expressed in pancreatic cancer cells (Oka, Tsuboi et al., 2004; Cheever, Allison et al., 2009), 38 out of 49 patients had received vaccination with WT1 peptide pulsed DCs with or without combination of other peptides such as MUC1, CEA and CA125 in this report. "
    Pancreatic Cancer - Molecular Mechanism and Targets, 12/2011; , ISBN: 978-953-51-0410-0
Show more